Table 3 Treatment effect on primary outcome and treatment effect on primary outcome by subgroup
Change in HbA1c (mmol/mol) from baseline to 12 months | ||||
|---|---|---|---|---|
Interventiona | Controla | Mean differenceb | P | |
HbA1c (mmol/mol) | −12.5 (30.72) | −13.0 (31.27) | −0.82 (−3.44 to 1.79) | 0.537 |
HbA1c at baseline | ||||
≤ 64 mmol/mol | 4.4 (16.39) | 2.7 (15.68) | 1.89 (−1.68 to 5.46) | < 0.0001 |
> 64 mmol/mol | −20.3 (32.59) | − 19.7 (33.76) | −2.36 (−5.70 to 0.97) | |
Age | ||||
< 55 years | −13.7 (30.29) | −15.8 (36.32) | −0.28 (−4.70 to 4.14) | 0.767 |
≥ 55 years | −11.7 (31.05) | − 11.0 (26.90) | −1.30 (− 4.50 to 1.90) | |
Gender | ||||
Male | −16.1 (31.88) | −15.3 (33.96) | −3.47 (−8.61 to 1.67) | 0.248 |
Female | − 11.1 (30.18) | −12.1 (30.17) | 0.17 (−2.88 to 3.22) | |
Duration of diabetes | ||||
< 7 years | −12.8 (29.48) | −14.4 (31.86) | − 1.20 (−4.62 to 2.22) | 0.050 |
≥ 7 years | − 12.2 (32.53) | −11.0 (30.37) | −0.37 (− 4.42 to 3.68) | |
Self-reported medication adherence at baseline | ||||
MARS < 25 | −11.5 (31.18) | − 10.7 (30.74) | − 1.51 (− 4.86 to 1.84) | 0.258 |
MARS = 25 | −14.4 (29.85) | − 16.6 (31.83) | 0.05 (− 4.18 to 4.29) | |